Fig. 7.

In vivo efficacy evaluation of the combination of TMZ and palbociclib in GBM PDX model. a Average tumor size versus time curves. The tumor growth was the most significantly delayed in the combination treatment group (TMZ and palbociclib) followed by palbociclib alone while TMZ alone and vehicle control group did not differ significantly. a, P < 0.01; b, P < 0.005. b Comparative neurosphere-generating ability. Tumor samples from each group were harvested and compared for their neurosphere-forming potential. The combination group showed the least number of neurospheres formed followed by palbociclib alone group, while TMZ and the control group showed similar degree of neurosphere-forming ability (highest). c Real-time PCR analysis. The combination group showed the lowest level of lncSNHG15, Sox2, CTNNB1, Sox2 and CDK6. a, P < 0.01; b, P < 0.005. d Immunohistochemical analysis of tumor samples. Comparatively, the immunohistochemical staining of CD206(M2 TAM marker), b-catenin and CDK6 was the lowest in the tumor samples collected from the combination group. The quantitative analysis of the IHC staining was represented by the H-score of each marker and represented by the dot-plot. **P < 0.01; ***P < 0.005